Myrtle Potter is a global healthcare innovator and the CEO of Sumitovant Biopharma, a technology-driven, patient-first biopharmaceutical company with a diverse portfolio of commercialized therapies and a pipeline of early- to late-stage assets.  Previously, Myrtle served as Vant Operating Chair of Roivant Sciences where she oversaw nine biopharmaceutical companies with more than 30 investigational drugs in 11 therapeutic areas and guided two of the companies through successful IPOs. Prior to Roivant, she served as CEO of Myrtle Potter & Company, a healthcare advisory firm she founded in 2005. Potter...read more